The role of inhibitor of DNA binding 1 in hematologic malignancies
10.19405/j.cnki.issn1000-1492.2025.12.024
- VernacularTitle:DNA 结合抑制因子 1 在血液肿瘤中的作用
- Author:
Yangjing Zhao
1
;
Yue You
1
;
Jiaxin Xu
1
;
Yan Pan
2
;
Tingjuan Zhang
1
;
Jingdong Zhou
1
Author Information
1. Dept of Laboratory Medicine , School of Medicine , Jiangsu University, Zhenjiang 212013
2. Dept of Clinical Laboratory, Lianshui County People ′s Hospital , Huai ′an 223400
- Publication Type:Review
- Keywords:
inhibitor of DNA binding 1;
differentiation inhibitor 1;
hematologic disorders;
acute myeloid leukemia;
therapeutic target;
prognostic biomarker
- From:
Acta Universitatis Medicinalis Anhui
2025;60(12):2384-2390
- CountryChina
- Language:Chinese
-
Abstract:
Abstract:Inhibitor of DNA binding 1(ID1) is a crucial regulator of cell differentiation and plays a significant role in maintaining normal hematopoietic differentiation and development. Due to the lack of DNA-binding motif, ID1 functions as a dominant-negative inhibitor of basic helix-loop-helix factors to antagonize their abilities to bind to DNA and transcriptionally regulate target genes. Abnormal expression of ID1 is strongly associated with various hematologic disorders, including myeloid and lymphoblastic leukemia, multiple myeloma and myeloproliferative neoplasms. ID1 acts as a potential oncogene by participating in multiple signaling pathways that promote the malignant proliferation, invasion and therapy resistance in leukemic cells. Significant strides have yielded promising antileukemic effects of ID1 inhibitors, both alone and in combination with targeted therapies against oncogenic signaling pathways. Here, we review the relationship between ID1 expression and the initiation and progression of blood disorders, and summarize the clinical significance of ID1 as a novel therapeutic target and potential prognostic biomarker for hematologic malignancies.
- Full text:2026030411110311151DNA结合抑制因子1在血液肿瘤中的作用_赵杨静.pdf
